Aclaris Q4 net loss $96.6M, revenue $9.2M; cash $203.9M; pipeline catalysts in H1 2025

Aclaris Therapeutics, Inc.

2024-FY EPS reported -$1.71 revenue$18,720,000

Net loss $96.6M in Q4 2024 vs $1.5M in Q4 2023; included $86.9M in-process R&D charge from bosakitug license.
Revenue $9.2M in Q4 2024 vs $17.6M in Q4 2023; full year revenue $18.7M vs $31.2M.
Cash, equivalents and marketable securities $203.9M at Dec 31, 2024; cash runway expected into 2028.
Phase 2 data from partner CTTQ in severe asthma and CRSwNP expected H1 2025; Phase 2b for bosakitug in AD enrollment H1 2025.
Leadership changes: Neal Walker named CEO; Hugh Davis appointed President and COO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.